Patents Assigned to SPRUCE BIOSCIENCES, INC.
  • Corticotropin releasing factor receptor antagonists
    Patent number: 12115166
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: October 15, 2024
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Methods and compositions for treating polycystic ovary syndrome
    Patent number: 12098152
    Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.
    Type: Grant
    Filed: February 9, 2023
    Date of Patent: September 24, 2024
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Christopher Barnes, David Karpf, Mustafa Noor
  • Corticotropin releasing factor receptor antagonists
    Patent number: 12005065
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: June 11, 2024
    Assignee: Spruce Biosciences, Inc.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Methods and compositions for treating polycystic ovary syndrome
    Patent number: 11858932
    Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: January 2, 2024
    Assignee: Spruce Biosciences, Inc.
    Inventors: Christopher Barnes, David Karpf, Mustafa Noor
  • Crystalline composition of tildacerfont and methods of use and preparation thereof
    Patent number: 11708372
    Abstract: Described herein are crystalline composition comprising a Corticotropin-releasing hormone receptor 1 (CRF1) antagonist, such as Compound 1: methods of making such crystalline composition, pharmaceutical compositions and medicaments comprising such crystalline composition, and methods of using such crystalline composition in the treatment of conditions, diseases, or disorders that would benefit from modulation of CRF.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: July 25, 2023
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Dasharatha Reddy, Ashokraj Rajagopal, Lu Wang, Christopher Barnes
  • Corticotropin releasing factor receptor antagonists
    Patent number: 11351177
    Abstract: The present invention provides novel pharmaceutical compositions comprising-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: June 7, 2022
    Assignee: Spruce Biosciences, Inc.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Corticotropin releasing factor receptor antagonists
    Patent number: 11344557
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 31, 2022
    Assignee: Spruce Biosciences, Inc.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Corticotropin releasing factor receptor antagonists
    Patent number: 11311549
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: April 26, 2022
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Methods for treating testicular and ovarian adrenal rest tumors
    Patent number: 11304950
    Abstract: Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: April 19, 2022
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber
  • Corticotropin releasing factor receptor antagonists
    Patent number: 11007201
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 18, 2021
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
    Publication number: 20210137935
    Abstract: The present invention provides novel pharmaceutical compositions comprising 3-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: August 14, 2018
    Publication date: May 13, 2021
    Applicant: Spruce Biosciences, Inc.
    Inventors: Alexis HOWERTON, Hal GERBER, Sami KARABORNI
  • Corticotropin releasing factor receptor antagonists
    Patent number: 10849908
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 1, 2020
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang